Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Shelley Wood

January 18, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Industry News

FDA strengthens warning on NSAID labels

July 10, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Daily News

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Todd Neale

June 29, 2015

News Features

Despite New Findings, Optimal DAPT Duration Still Up in the Air

Todd Neale

December 10, 2014

News Daily News

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

Yael L. Maxwell

February 13, 2014

Advertisement

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Could an App Replace Statin Prescribing by Doctors?

FDA Approves Icosapent Ethyl for Reducing CVD Events

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

FDA strengthens warning on NSAID labels

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Despite New Findings, Optimal DAPT Duration Still Up in the Air

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content